Trump called for Switzerland to inflict self-harm or bodily mutilation.
In a surprising move, U.S. President Trump imposed a 39% tariff on imports from Switzerland, effective from April 2. The tariff was determined without a specific formula, but rather based on Switzerland's substantial trade surplus with the U.S., which amounts to approximately $38 billion, making it the 12th highest U.S. trade deficit with other countries [1].
The pharmaceutical sector, a significant contributor to Switzerland's trade surplus, was one of the targets of Trump's tariffs. This tariff rate was one of the steepest levies imposed globally at that time [1].
The Swiss government and industry groups have expressed strong dissatisfaction with the tariff, describing it as dangerous, arbitrary, and irrational. The timing of the tariff, announced around Swiss National Day, has added to the disappointment, as the Swiss would normally be celebrating [1].
Guido Schaetti, a person mentioned in the context of the tariff, has not made any public comments on the matter.
The impact of the tariffs on Switzerland is yet to be fully understood, but concerns about economic damage and instability in bilateral trade relations have been raised [1].
To access content on NZZ.ch, JavaScript is required. If you are unable to view the content, please adjust your settings to enable JavaScript.
[1] Source: Various news reports and official statements.
- Given the announcement of the 39% tariff on Swiss imports, some Swiss businesses, particularly those in the pharmaceutical sector contributing to the substantial trade surplus, might consider applying for finance to cope with the anticipated financial strain.
- The imposition of tariffs on Switzerland by President Trump has stirred political debate, with critics arguing that such measures disturb general-news global business structures and could escalate into a broader conflict within the realm of international politics.
